10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      miR-190-5p in human diseases

      review-article
      1 , 2 , 3 , 4 , , 1 , 2 , 3 , 4 ,
      Cancer Cell International
      BioMed Central
      miR-190, Cancer, Tumorigenesis, Progression, Biomarker

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          miRNAs, a major class of small noncoding RNAs approximately 18–25 nucleotides in length, function by repressing the expression of target genes through binding to complementary sequences in the 3′-UTRs of target genes. Emerging evidence has highlighted their important roles in numerous diseases, including human cancers. Recently, miR-190 has been shown to be dysregulated in various types of human cancers that participates in cancer-related biological processes, including proliferation, apoptosis, metastasis, drug resistance, by regulating associated target genes, and to predict cancer diagnosis and prognosis. In this review, we summarized the roles of miR-190-5p in human diseases, especially in human cancers. Then we classified its target genes in tumorigenesis and progression, which might provide evidence for cancer diagnosis and prognosis, promising tools for cancer treatment, or leads for further investigation.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis

          Transforming growth factor β (TGF-β) is a secreted cytokine that regulates cell proliferation, migration, and the differentiation of a plethora of different cell types. Consistent with these findings, TGF-β plays a key role in controlling embryogenic development, inflammation, and tissue repair, as well as in maintaining adult tissue homeostasis. TGF-β elicits a broad range of context-dependent cellular responses, and consequently, alterations in TGF-β signaling have been implicated in many diseases, including cancer. During the early stages of tumorigenesis, TGF-β acts as a tumor suppressor by inducing cytostasis and the apoptosis of normal and premalignant cells. However, at later stages, when cancer cells have acquired oncogenic mutations and/or have lost tumor suppressor gene function, cells are resistant to TGF-β-induced growth arrest, and TGF-β functions as a tumor promotor by stimulating tumor cells to undergo the so-called epithelial-mesenchymal transition (EMT). The latter leads to metastasis and chemotherapy resistance. TGF-β further supports cancer growth and progression by activating tumor angiogenesis and cancer-associated fibroblasts and enabling the tumor to evade inhibitory immune responses. In this review, we will consider the role of TGF-β signaling in cell cycle arrest, apoptosis, EMT and cancer cell metastasis. In particular, we will highlight recent insights into the multistep and dynamically controlled process of TGF-β-induced EMT and the functions of miRNAs and long noncoding RNAs in this process. Finally, we will discuss how these new mechanistic insights might be exploited to develop novel therapeutic interventions.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Cancer metastases: challenges and opportunities

            Cancer metastasis is the major cause of cancer morbidity and mortality, and accounts for about 90% of cancer deaths. Although cancer survival rate has been significantly improved over the years, the improvement is primarily due to early diagnosis and cancer growth inhibition. Limited progress has been made in the treatment of cancer metastasis due to various factors. Current treatments for cancer metastasis are mainly chemotherapy and radiotherapy, though the new generation anti-cancer drugs (predominantly neutralizing antibodies for growth factors and small molecule kinase inhibitors) do have the effects on cancer metastasis in addition to their effects on cancer growth. Cancer metastasis begins with detachment of metastatic cells from the primary tumor, travel of the cells to different sites through blood/lymphatic vessels, settlement and growth of the cells at a distal site. During the process, metastatic cells go through detachment, migration, invasion and adhesion. These four essential, metastatic steps are inter-related and affected by multi-biochemical events and parameters. Additionally, it is known that tumor microenvironment (such as extracellular matrix structure, growth factors, chemokines, matrix metalloproteinases) plays a significant role in cancer metastasis. The biochemical events and parameters involved in the metastatic process and tumor microenvironment have been targeted or can be potential targets for metastasis prevention and inhibition. This review provides an overview of these metastasis essential steps, related biochemical factors, and targets for intervention.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              MicroRNA: function, detection, and bioanalysis.

                Bookmark

                Author and article information

                Contributors
                86-022-23340123 , yuyue@tmu.edu.cn
                86-022-23340123 , caoxuchen@tmu.edu.cn
                Journal
                Cancer Cell Int
                Cancer Cell Int
                Cancer Cell International
                BioMed Central (London )
                1475-2867
                7 October 2019
                7 October 2019
                2019
                : 19
                : 257
                Affiliations
                [1 ]ISNI 0000 0004 1798 6427, GRID grid.411918.4, The First Department of Breast Cancer, National Clinical Research Center for Cancer, , Tianjin Medical University Cancer Institute and Hospital, ; Huan-Hu-Xi Road, Hexi District, Tianjin, 300060 China
                [2 ]ISNI 0000 0004 1798 6427, GRID grid.411918.4, Key Laboratory of Cancer Prevention and Therapy, ; Tianjin, 300060 China
                [3 ]Tianjin’s Clinical Research Center for Cancer, Tianjin, 300060 China
                [4 ]ISNI 0000 0000 9792 1228, GRID grid.265021.2, Key Laboratory of Breast Cancer Prevention and Therapy, , Tianjin Medical University, Ministry of Education, ; Tianjin, 300060 China
                Author information
                http://orcid.org/0000-0003-3216-6673
                Article
                984
                10.1186/s12935-019-0984-x
                6781386
                31624470
                76e5ca25-c753-459a-b389-4df33b980210
                © The Author(s) 2019

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 30 July 2019
                : 27 September 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100001809, National Natural Science Foundation of China;
                Award ID: 81502518
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100006606, Natural Science Foundation of Tianjin City;
                Award ID: 17JCQNJC10400
                Award Recipient :
                Categories
                Review
                Custom metadata
                © The Author(s) 2019

                Oncology & Radiotherapy
                mir-190,cancer,tumorigenesis,progression,biomarker
                Oncology & Radiotherapy
                mir-190, cancer, tumorigenesis, progression, biomarker

                Comments

                Comment on this article